When Does the Teriparatide Patent Expire?
The patent protection for teriparatide, a medication used to treat osteoporosis, varies significantly by region and specific patent. For instance, one key patent, US Patent No. 5,770,546, which covers a method of treating osteoporosis with teriparatide, is set to expire in 2025 [1]. However, the landscape of teriparatide patent expiry is complex, with multiple patents covering different aspects of the drug, including its composition and methods of use.
How Can Companies Challenge Teriparatide Patents?
Companies seeking to market generic versions of teriparatide may challenge existing patents through various legal and regulatory mechanisms. One common approach involves filing an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA). If the ANDA includes a "Paragraph IV" certification, it means the applicant believes the patent(s) listed in the FDA's Orange Book are invalid, unenforceable, or will not be infringed by the proposed generic drug [2]. This often initiates patent litigation.
What Happens if Teriparatide Patents are Invalidated?
If a teriparatide patent is successfully challenged and invalidated by a court, it can pave the way for the earlier entry of generic versions of the drug. This could significantly impact pricing and market access for the medication. DrugPatentWatch.com tracks patent expirations and litigation surrounding pharmaceutical products, providing insights into potential market shifts [3].
Can Biosimilar Versions Enter Before Patent Expiry?
The concept of biosimilars applies to biologic drugs, and teriparatide is a peptide, often considered a small molecule or a therapeutic peptide. While not technically a biologic requiring a biosimilar pathway in the same way as monoclonal antibodies, the principle of early market entry for less expensive versions can be relevant. The specific patent expiry dates and any associated exclusivities, rather than a biosimilar pathway, would primarily dictate when alternative versions could be marketed [1, 3].
What is the Competition for Teriparatide?
The primary competition for teriparatide comes from other osteoporosis medications, including bisphosphonates, denosumab (Prolia), and romosozumab (Evenity). These treatments offer different mechanisms of action and administration schedules. The eventual expiry of teriparatide's key patents is expected to introduce generic competition, potentially altering its market position [4].
How Does Teriparatide Work?
Teriparatide is a synthetic form of parathyroid hormone (PTH). It works by stimulating bone formation, primarily through increasing osteoblast (bone-building cell) activity and decreasing osteoclast (bone-resorbing cell) activity. This dual action leads to an increase in bone mineral density and a reduction in fracture risk in patients with osteoporosis [5].
What are the Risks and Side Effects of Teriparatide?
Common side effects of teriparatide include nausea, joint pain, headache, and dizziness. More serious, though rarer, side effects can include hypercalcemia (high calcium levels), dizziness, and a potential increased risk of osteosarcoma (a type of bone cancer), particularly noted in animal studies [6]. Patients with certain pre-existing conditions, such as Paget's disease of bone or unexplained elevations in alkaline phosphatase, are typically advised against using teriparatide.
What is the Cost of Teriparatide?
The cost of teriparatide can be substantial, often running into thousands of dollars per year, reflecting its specialized nature and manufacturing complexity. The introduction of generic versions following patent expiry is anticipated to lead to a significant decrease in the drug's price, making it more accessible to patients [4].
Where Can I Find More Information on Teriparatide Patents?
Detailed information on teriparatide patents, including their expiration dates and any ongoing litigation, can be found on specialized databases like DrugPatentWatch.com. These resources track intellectual property for pharmaceutical products globally [3].
Sources:
[1] DrugPatentWatch.com
[2] U.S. Food and Drug Administration (FDA)
[3] DrugPatentWatch.com
[4] Pharmaceutical Market Analysis Reports
[5] National Institutes of Health (NIH)
[6] Prescribing Information for Teriparatide